{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:35:01Z","timestamp":1786649701569,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Surgery, stereotactic radiosurgery (SRS), whole brain radiotherapy (WBRT), or a combination of any of these are all local therapy options for brain metastasis. In this study, we report outcomes of patients with brain metastasis from breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This was a retrospective single-institution study. Records of patients with breast cancer registered in our department from 2016 to 2023 were evaluated. Patients with radiological or histopathological proof of brain metastasis who had received any form of cranial radiotherapy were included in the study. Various patient-related, disease-related, treatment-related, and dosimetric variables were recorded in this study. For the patients receiving WBRT, time dose and fractionation were recorded. Patients were stratified into WBRT group and SRS group for the purpose of survival analysis. Survival analysis was performed using Kaplan\u2013Meir method, and survival between groups was compared using the log rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total 98 patients were included for analysis in the study. The mean age of the study population was 46.42 years. All were female. Forty-four (45%) patients were Stage III at diagnosis, and 46 (47%) patients were metastatic at diagnosis. The median interval from diagnosis to brain metastasis was 18.1 months (IQR 9.5\u201334.4 months). Fourteen (14.3%) patients presented with brain metastasis at diagnosis. Sixty-eight (69.4%) patients had less than or equal to 5 lesions. Fourteen (14.3%) patients underwent surgery for brain metastasis. All patients received some form of cranial radiotherapy. Forty-seven (48%) patients received SRS, and 51 (52%) received WBRT. Twenty-nine (61.7%) patients received single-fraction SRS, whereas 18 (18.3%) received fractionated SRT. The 1-year event-free survival (EFS) was 41% in the WBRT group and 49% in the SRS group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.410). The 1-year overall survival (OS) was 49% in the SRS group and 54% in the SRS group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.293).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this retrospective study, there was no significant difference in survival outcomes with SRS or WBRT in breast cancer patients with brain metastasis. There is a need for dedicated prospective randomized trials to determine the optimal treatment sequence in metastatic breast cancer with brain metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_424_25","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:00:57Z","timestamp":1767200457000},"page":"1361-1366","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Stereotactic radiosurgery versus whole brain radiotherapy in patients of breast cancer with brain metastasis \u2013 A retrospective single-institution analysis"],"prefix":"10.4103","volume":"21","author":[{"given":"Budhi","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Krishna Vamsi","family":"Gade","sequence":"additional","affiliation":[{"name":"Proton Beam Therapy, The Christie NHS Foundation Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngangom","family":"Robert","sequence":"additional","affiliation":[{"name":"Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"R1-20260102","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260102","first-page":"56","article-title":"Ali ProfI, Wani W, Saleem K, Correspondence. Cancer scenario in India with future perspectives","volume":"8","year":"2011","journal-title":"Cancer Ther"},{"key":"R3-20260102","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.70029","article-title":"Whole brain radiotherapy versus stereotactic radiosurgery in breast cancer patients with brain metastases-A phase 3 open label randomized study","author":"Yadav","year":"2025","journal-title":"Asia Pac J Clin Oncol"},{"key":"R4-20260102","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/bjc.2013.6","article-title":"Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: A population-based study","volume":"108","author":"Walters","year":"2013","journal-title":"Br J Cancer"},{"key":"R5-20260102","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","article-title":"Extending survival with chemotherapy in metastatic breast cancer","volume":"10","author":"O'Shaughnessy","year":"2005","journal-title":"Oncologist"},{"key":"R6-20260102","first-page":"307","article-title":"Breast cancer brain metastases: New directions in systemic therapy","volume":"7","author":"Lin","year":"2013","journal-title":"Ecancermedicalscience"},{"key":"R7-20260102","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.breast.2011.07.017","article-title":"Breast cancer subtypes and outcomes of central nervous system metastases","volume":"20","author":"Arslan","year":"2011","journal-title":"Breast"},{"key":"R8-20260102","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11060-016-2075-3","article-title":"Brain metastasis in breast cancer: A comprehensive literature review","volume":"127","author":"Rostami","year":"2016","journal-title":"J Neurooncol"},{"key":"R9-20260102","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer\u2606","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"R10-20260102","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"R11-20260102","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"R12-20260102","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastasesa randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"R13-20260102","first-page":"e13","article-title":"Synchronous primary carcinoma of breast and ovary versus ovarian metastases. Semin Oncol","volume":"42","author":"Yadav","year":"2015"},{"key":"R14-20260102","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"R17-20260102","doi-asserted-by":"crossref","first-page":"650","DOI":"10.18632\/oncotarget.27453","article-title":"Risk factors for breast cancer brain metastases: A systematic review","volume":"11","author":"Koniali","year":"2020","journal-title":"Oncotarget"},{"key":"R18-20260102","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): A multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"R19-20260102","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.6186","article-title":"Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): A phase III, noninferiority, randomized controlled trial","author":"Kayama","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"R20-20260102","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","article-title":"Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials","volume":"37","author":"Gaspar","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R21-20260102","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation therapy for brain metastases: An ASTRO clinical practice guideline","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"R22-20260102","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1017\/S1460396921000029","article-title":"LINAC-based stereotactic radiosurgery\/radiotherapy for brain metastases in patients with breast cancer","volume":"21","author":"Gupta","year":"2022","journal-title":"J Radiother Pract"},{"key":"R23-20260102","first-page":"70","article-title":"The individual risk of symptomatic radionecrosis after brain metastasis radiosurgery is predicted by a continuous function of the V12Gy","volume":"27","author":"Daisne","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"R24-20260102","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic radiosurgery for brain metastases: Analysis of outcome and risk of brain radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol Lond Engl"},{"key":"R25-20260102","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/annonc\/mdu488","article-title":"Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer","volume":"26","author":"Cao","year":"2015","journal-title":"Ann Oncol"},{"key":"R26-20260102","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"R27-20260102","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA\u2020","volume":"26","author":"Krop","year":"2015","journal-title":"Ann Oncol"},{"key":"R28-20260102","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3390\/cancers15082278","article-title":"Interaction between radiation therapy and targeted therapies in HER2-positive breast cancer: Literature review, levels of evidence for safety and recommendations for optimal treatment sequence","volume":"15","author":"Debbi","year":"2023","journal-title":"Cancers"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_424_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:57:15Z","timestamp":1786647435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_424_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_424_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-02-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}